• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited

    11/24/25 8:58:20 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care
    Get the next $HKPD alert in real time by email
    6-K 1 ea0265848-01.htm CURRENT REPORT

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _______________

    FORM 6-K

    _______________

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
    OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of November 2025

    Commission File Number 001-42468

    _______________

    Hong Kong Pharma Digital Technology Holdings Limited
    (Registrant’s Name)

    _______________

    Room B1, 5/F., Well Town Industrial Building,
    13 Ko Fai Road, Yau Tong, Kowloon
    Hong Kong
    (Address of principal executive office)

    _______________

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒            Form 40-F ☐

       

     

    Annual General Meeting of Shareholders

    On November 24, 2025, Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) announced that it will hold an annual general meeting of shareholders (the “Meeting”) on December 12, 2025 at 10:00 a.m., Hong Kong Time (December 11, 2025, at 9:00 p.m., Eastern Time). The Meeting will be held at Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong.

    In connection with the annual general meeting of shareholders of the Company, the Company hereby furnishes the following documents which are incorporated by reference herein:

    Exhibits

    Exhibit No.

     

    Description

    99.1

     

    Proxy Statement and Notice of Annual General Meeting of Shareholders, dated November 24, 2025

    99.2

     

    Form of Proxy Card of Annual General Meeting of Shareholders

    99.3

     

    Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan

    99.4

     

    Form of fourth amended and restated memorandum and articles of association

    1

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Hong Kong Pharma Digital Technology Holdings Limited

       

    By:

     

    /s/ Chenyu Liang

       

    Name:

     

    Chenyu Liang

       

    Title:

     

    Director and Chief Executive Officer

    Date: November 24, 2025

    2

    Get the next $HKPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HKPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HKPD
    SEC Filings

    View All

    SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd

    EFFECT - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    4/9/26 12:15:14 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd

    F-1 - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    3/27/26 3:19:24 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd

    6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    3/26/26 7:48:08 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

    HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the "Notification Letter") dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the min

    1/16/26 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

    HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific

    12/17/25 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

    HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an

    3/28/25 4:50:00 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    Financials

    Live finance-specific insights

    View All

    Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

    HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an

    3/28/25 4:50:00 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

    HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific

    12/17/25 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care